Jim Simons’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$494K Sell
101,427
-697
-0.7% -$3.9K ﹤0.01% 2605
2025
Q4
$683K Buy
102,124
+15,276
+18% +$90.6K ﹤0.01% 2451
2025
Q3
$381K Buy
86,848
+7,650
+10% +$36.3K ﹤0.01% 2904
2025
Q2
$351K Sell
79,198
-9,172
-10% -$38.3K ﹤0.01% 2986
2025
Q1
$500K Buy
88,370
+17,392
+25% +$223K ﹤0.01% 2744
2024
Q4
$1.5M Sell
70,978
-1,430
-2% -$32.8K ﹤0.01% 2235
2024
Q3
$1.95M Sell
72,408
-2,120
-3% -$62.5K ﹤0.01% 2038
2024
Q2
$2.12M Buy
74,528
+4,280
+6% +$150K ﹤0.01% 1851
2024
Q1
$2.98M Sell
70,248
-1,790
-2% -$80.5K ﹤0.01% 1772
2023
Q4
$3.85M Sell
72,038
-2,430
-3% -$110K 0.01% 1509
2023
Q3
$3.2M Sell
74,468
-753
-1% -$34.7K 0.01% 1563
2023
Q2
$4.13M Buy
75,221
+2,220
+3% +$122K 0.01% 1535
2023
Q1
$3.07M Sell
73,001
-430
-0.6% -$12.8K ﹤0.01% 1763
2022
Q4
$2.03M Sell
73,431
-11,716
-14% -$289K ﹤0.01% 2055
2022
Q3
$2.18M Sell
85,147
-14,979
-15% -$496K ﹤0.01% 1957
2022
Q2
$3.6M Buy
100,126
+5,281
+6% +$238K ﹤0.01% 1787
2022
Q1
$5.89M Buy
94,845
+4,250
+5% +$251K 0.01% 1470
2021
Q4
$6.39M Sell
90,595
-17,050
-16% -$1.21M 0.01% 1350
2021
Q3
$7.51M Sell
107,645
-15,690
-13% -$1.25M 0.01% 1206
2021
Q2
$10.3M Sell
123,335
-19,430
-14% -$1.37M 0.01% 1153
2021
Q1
$7.79M Buy
142,765
+21,120
+17% +$1.03M 0.01% 1355
2020
Q4
$5.22M Sell
121,645
-3,490
-3% -$130K 0.01% 1558
2020
Q3
$3.77M Buy
125,135
+21,922
+21% +$737K ﹤0.01% 1744
2020
Q2
$3.2M Buy
103,213
+35,530
+52% +$957K ﹤0.01% 1901
2020
Q1
$1.5M Buy
67,683
+14,083
+26% +$382K ﹤0.01% 2213
2019
Q4
$1.64M Buy
53,600
+2,079
+4% +$59.8K ﹤0.01% 2415
2019
Q3
$1.58M Sell
51,521
-38,579
-43% -$959K ﹤0.01% 2401
2019
Q2
$1.8M Buy
90,100
+27,950
+45% +$819K ﹤0.01% 2383
2019
Q1
$2.68M Sell
62,150
-7,841
-11% -$284K ﹤0.01% 2164
2018
Q4
$2.23M Sell
69,991
-17,979
-20% -$709K ﹤0.01% 2176
2018
Q3
$4.62M Buy
87,970
+13,223
+18% +$742K ﹤0.01% 1855
2018
Q2
$4M Sell
74,747
-983
-1% -$50.4K ﹤0.01% 1926
2018
Q1
$3.79M Buy
75,730
+14,517
+24% +$651K ﹤0.01% 1998
2017
Q4
$2.02M Buy
61,213
+708
+1% +$23.9K ﹤0.01% 2343
2017
Q3
$2.27M Buy
60,505
+1,505
+3% +$44.5K ﹤0.01% 2236
2017
Q2
$1.5M Buy
59,000
+2,950
+5% +$73K ﹤0.01% 2408
2017
Q1
$1.46M Buy
56,050
+3,130
+6% +$90.2K ﹤0.01% 2395
2016
Q4
$1.61M Buy
52,920
+2,050
+4% +$52.1K ﹤0.01% 2326
2016
Q3
$1.38M Sell
50,870
-2,550
-5% -$70.8K ﹤0.01% 2409
2016
Q2
$1.53M Sell
53,420
-2,330
-4% -$74.1K ﹤0.01% 2355
2016
Q1
$1.68M Sell
55,750
-930
-2% -$26.4K ﹤0.01% 2320
2015
Q4
$1.97M Sell
56,680
-3,430
-6% -$117K ﹤0.01% 2120
2015
Q3
$2.27M Sell
60,110
-2,390
-4% -$111K 0.01% 1916
2015
Q2
$3.56M Buy
62,500
+1,580
+3% +$89.9K 0.01% 1665
2015
Q1
$3.55M Buy
60,920
+948
+2% +$50.9K 0.01% 1581
2014
Q4
$3.4M Sell
59,972
-3,238
-5% -$154K 0.01% 1501
2014
Q3
$2.58M Sell
63,210
-10,830
-15% -$498K 0.01% 1535
2014
Q2
$3.37M Buy
74,040
+15,583
+27% +$655K 0.01% 1456
2014
Q1
$2.77M Buy
58,457
+9,537
+19% +$434K 0.01% 1589
2013
Q4
$2.3M Sell
48,920
-6,501
-12% -$284K 0.01% 1683
2013
Q3
$2.21M Buy
55,421
+6,750
+14% +$265K 0.01% 1613
2013
Q2
$1.73M Buy
+48,671
New +$1.86M ﹤0.01% 1658

Other funds holding HBIO

Jim Simons's HBIO Position: Q1 2026 in Review

Jim Simons reduced its Harvard Bioscience (HBIO) stake by 0.68% in Q1 2026, selling an estimated $3.9K and leaving 101,427 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Jim Simons first reported a position in HBIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.3M in Q2 2021. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Jim Simons held 101,427 shares of Harvard Bioscience worth $494K as of Q1 2026.
  • Jim Simons sold 697 Harvard Bioscience shares in Q1 2026, an estimated $3.9K.
  • Harvard Bioscience made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2605 holding.
  • Jim Simons first reported a position in Harvard Bioscience in Q2 2013 and has held it in 52 quarters since.
  • Jim Simons's Harvard Bioscience position peaked at $10.3M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.